GLP1R and metabolic dysfunction-associated steatotic liver disease: Current research limitations that require future resolution include the following: (1) precision medicine: stratifying responders through genomic/proteomic analysis; (2) combination therapy: pairing resmetirom with GLP-1 agonists or FXR modulators to enhance efficacy; and (3) disease modification: extending trials to early NAFLD and compensated cirrhosis (F4).